Ceftolozane/tazobactam as a treatment for multidrug-resistant P. Aeruginosa in a ventricle-peritoneal shunt

• Autores: Felix Gómez de Rueda, Bárbara Cancela Díez, María Eugenia Tena Sempere, Myriam Cardenas Anton, Antonio Gálvez del Postigo Ruiz
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 22, Nº. 2, 2020, págs. 110-113
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Ceftolozane-tazobactam (C-T) is a combination at fixed doses of a cephalosporin and a beta-lactamase inhibitor of recent introduction in infectious pathology, authorized so far for the treatment of serious urinary tract infections, intra-abdominal and recently respiratory infections. However, it seems to have a special activity against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, except AmpC or carbapenemases (except OXA 48) that are resistant. This makes it a reserve therapy to treat infections by drug-resistant P. aeruginosa (DR-PSA), a very frequent germ and difficult to eradicate in our Intensive Care Units (ICU). The main objective of this clinical case is to share our sentinel experience in the treatment of a cranial wound infection with central nervous system involvement by DR-PSA, consequence of collaboration between the ICU and the Hospital Pharmacy Unit. © 2020 Rasgo Editorial S.A.. All rights reserved.